Zenflow, a South San Francisco, CA-based medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia, closed a $24m Series C financing round.
The round includes new investor Cook Medical as well as existing investors Invus Opportunities, F-Prime Capital, Medical Technology Venture Partners and others.
Led by Shreya Mehta, CEO, Zenflow is a medical device company dedicated to improving treatment for patients suffering from urinary obstruction caused by enlarged prostate. The innovative Spring® technology relies on a small spring-like coil that gently props open the urethra, restoring its normal function while preserving the natural anatomy. The Zenflow Spring System is an investigational device and is not approved for commercial sale.
The company intends to use the funds for Pre-Market Approval (PMA) submission and preparation for commercialization upon FDA approval of its Spring® System.
The progress towards FDA approval is based on its solid foundation of clinical research, covering over 300 patients in multiple studies including its most recent pivotal clinical trial BREEZE™, a prospective, multicenter, controlled study in over 200 patients with lower urinary tract symptoms due to enlarged prostate.
